198 related articles for article (PubMed ID: 33690222)
1. Vaccine delivery alerts innate immune systems for more immunogenic vaccination.
Li Z; Cao Y; Li Y; Zhao Y; Chen X
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33690222
[TBL] [Abstract][Full Text] [Related]
2. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
4. DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination.
Hayashi T; Momota M; Kuroda E; Kusakabe T; Kobari S; Makisaka K; Ohno Y; Suzuki Y; Nakagawa F; Lee MSJ; Coban C; Onodera R; Higashi T; Motoyama K; Ishii KJ; Arima H
Front Immunol; 2018; 9():2619. PubMed ID: 30515151
[TBL] [Abstract][Full Text] [Related]
5. Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.
Marty-Roix R; Vladimer GI; Pouliot K; Weng D; Buglione-Corbett R; West K; MacMicking JD; Chee JD; Wang S; Lu S; Lien E
J Biol Chem; 2016 Jan; 291(3):1123-36. PubMed ID: 26555265
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
7. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.
Kistner O; Crowe BA; Wodal W; Kerschbaum A; Savidis-Dacho H; Sabarth N; Falkner FG; Mayerhofer I; Mundt W; Reiter M; Grillberger L; Tauer C; Graninger M; Sachslehner A; Schwendinger M; Brühl P; Kreil TR; Ehrlich HJ; Barrett PN
PLoS One; 2010 Feb; 5(2):e9349. PubMed ID: 20186321
[TBL] [Abstract][Full Text] [Related]
8. Micro-fractional epidermal powder delivery for improved skin vaccination.
Chen X; Kositratna G; Zhou C; Manstein D; Wu MX
J Control Release; 2014 Oct; 192():310-6. PubMed ID: 25135790
[TBL] [Abstract][Full Text] [Related]
9. The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype.
Grødeland G; Mjaaland S; Tunheim G; Fredriksen AB; Bogen B
PLoS One; 2013; 8(11):e80008. PubMed ID: 24244595
[TBL] [Abstract][Full Text] [Related]
10. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
11. The Interleukin-33-Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine.
Williams CM; Roy S; Califano D; McKenzie ANJ; Metzger DW; Furuya Y
J Virol; 2021 Oct; 95(22):e0059821. PubMed ID: 34468174
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant.
Cao Y; Zhu X; Hossen MN; Kakar P; Zhao Y; Chen X
Nat Commun; 2018 Sep; 9(1):3695. PubMed ID: 30209303
[TBL] [Abstract][Full Text] [Related]
13. Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses.
Seydoux E; Liang H; Dubois Cauwelaert N; Archer M; Rintala ND; Kramer R; Carter D; Fox CB; Orr MT
J Immunol; 2018 Jul; 201(1):98-112. PubMed ID: 29769270
[TBL] [Abstract][Full Text] [Related]
14. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
[TBL] [Abstract][Full Text] [Related]
15. Implantable microneedles with an immune-boosting function for effective intradermal influenza vaccination.
Chen YH; Lai KY; Chiu YH; Wu YW; Shiau AL; Chen MC
Acta Biomater; 2019 Oct; 97():230-238. PubMed ID: 31362139
[TBL] [Abstract][Full Text] [Related]
16. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of A/H1N1/2009 split inactivated influenza A vaccine (GC1115) in mice and ferrets.
Han HJ; Song MS; Park SJ; Byun HY; Robles NJC; Ha SH; Choi YK
J Microbiol; 2019 Feb; 57(2):163-169. PubMed ID: 30706345
[TBL] [Abstract][Full Text] [Related]
18. Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.
Russell RF; McDonald JU; Lambert L; Tregoning JS
J Virol; 2016 May; 90(9):4735-4744. PubMed ID: 26912628
[TBL] [Abstract][Full Text] [Related]
19. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
20. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
